TD Cowen raised the firm’s price target on Regeneron to $1,020 from $1,000 and keeps an Outperform rating on the shares. The firm updated its model to include the disclosed Intellia $30MM IPR&D expense too.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
- Regeneron price target raised to $1,020 from $935 at Barclays
- Regeneron price target raised to $1,104 from $941 at Morgan Stanley
- Regeneron price target raised to $956 from $895 at Piper Sandler
- Regeneron, Sanofi announce U.S. FDA updated the label for Dupixent
